- Compliance & Regulation, Risk
Share
The U.S. Drug Enforcement Agency’s (DEA) recent proposal to reclassify cannabis from a Schedule I to a Schedule III drug introduces a complex array of opportunities and challenges for banks. While this potential change could significantly reduce the stigma and regulatory burdens associated with banking the cannabis industry, it also presents a nuanced risk landscape that banks must approach carefully, writes Senior Editor Michael Bender in a new RMA Journal article. Here are some key takeaways:
Still, Jutkowitz says risk managers “might advise less caution given the regulatory trajectory.”
“There will be some banks that look at [reclassification] as a path to federal legalization and will no longer worry about reputational risk,” he said. “Whatever concerns they had about the Fed seizing their loan collateral or suspending their banking licenses may go away.”
Read the complete article.
Become a member to unlock exclusive content, connect with industry experts, and gain access to valuable resources. If your employer is an institutional member, activate your ProSight membership benefits with a simple email address.